All conditions

Huntington's Disease

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

259
Trials on record
37
Recruiting now
3
Australian sites
2
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Huntington's Disease →

Get alerts when Huntington's Disease trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Huntington's Disease

Huntington's disease is an inherited condition that causes nerve cells in the brain to gradually break down over time. It affects movement, thinking, and emotions, and symptoms typically appear in a person's 30s or 40s, though they can start earlier or later. Because it is caused by a change in a single gene, a parent with Huntington's has a 50% chance of passing that gene change on to each of their children. Symptoms often include involuntary movements, difficulty with balance and coordination, trouble concentrating or remembering things, and changes in mood or behaviour.

In Australia, it is estimated that around 2,000 people are living with Huntington's disease, with a further 7,000 or more who may be at risk due to family history. There are Huntington's disease support organisations and specialist clinics across the country, including services connected to major hospitals in most states and territories. These services bring together neurologists, genetic counsellors, physiotherapists, psychologists, and social workers who understand the condition and can provide coordinated support.

At present there is no cure for Huntington's disease, and treatment focuses on managing symptoms and maintaining quality of life for as long as possible. This can include medications to help with movement difficulties or mood changes, as well as therapies such as physiotherapy, speech pathology, and occupational therapy. Research into potential disease-modifying treatments is actively underway around the world, and Australian patients may have opportunities to participate in clinical trials. Connecting with a specialist clinic and a support organisation like Huntington's NSW ACT or a state-based equivalent can be a helpful starting point for understanding the options available.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Huntington's Disease in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Huntington's Disease currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Huntington's Disease.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Huntington's Disease by country. Australia is highlighted.

Showing the top 10 of 30 countries with trial sites.

Clinical trials for Huntington's Disease

Showing 52 of 52 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01590888 · Prana Biotechnology Limited Phase 2 · 2 countries Completed
Completed Phase 2 Est. completion 1 July 2013
🇦🇺 AU🇺🇸 US

Who might be able to join this trial: - You are willing and able to sign a consent form agreeing to take part in the study. - You have been diagnosed with Huntington's disease, including both the physical symptoms and a specific genetic marker (a CAG repeat number of 36 or higher). - Your level of day-to-day functionin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01795859 · Teva Branded Pharmaceutical Products R&D, Inc. Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 5 December 2014
🇦🇺 AU🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - You must be at least 18 years old (or the legal age of adulthood, whichever is older) at the time of screening. - You must have been diagnosed with Huntington's Disease (HD). - You must be able to swallow the study medication whole. - If you are a woman who could become pregnant,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01897896 · Auspex Pharmaceuticals, Inc. Phase 3 · 3 countries Completed
Completed Phase 3 Est. completion 21 August 2017
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older (or the age of legal adulthood in your location, whichever is older) - You have been diagnosed with Huntington's disease (HD) confirmed by a genetic test showing an expanded CAG repeat number of 37 or higher - You either completed a specific pre...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02006472 · Prilenia Phase 2 · 12 countries Completed
Completed Phase 2 Est. completion 16 December 2015
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL +4 more

**Who might be able to join this trial:** - You have been diagnosed with Huntington's disease (HD), confirmed by a specific genetic marker (36 or more CAG repeats on a gene test) - You are male or female, aged 21 or older, and your HD symptoms began after the age of 18 - If you are a woman who could become pregnant, yo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03761849 · Hoffmann-La Roche Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 24 March 2022
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇨🇦 CA🇨🇱 CL🇩🇰 DK🇫🇷 FR🇩🇪 DE +10 more

Who might be able to join this trial: - You have been diagnosed with manifest (confirmed, active) Huntington's Disease, based on a specific scoring system used by doctors (called a DCL score of 4) - You are largely independent in your daily life, scoring 70 or above on an Independence Scale used to measure how well som...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05032196 · Wave Life Sciences USA, Inc. Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 24 May 2024
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇵🇱 PL +2 more

**Who might be able to join this trial:** - You have a specific genetic marker (called the "A variant of SNP3") on the same gene affected by Huntington's disease — your doctor can check this through genetic testing - You are a man or woman aged between 25 and 60 years old, and you are able to walk - You have been clini...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05107128 · Supernus Pharmaceuticals, Inc. Phase 2 · 4 countries Completed
Completed Phase 2 Est. completion 4 September 2024
🇦🇺 AU🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been genetically confirmed to have Huntington's disease, with a specific gene change (CAG repeat of 36 or more) detected by testing. - Your Huntington's disease is at a mild-to-moderate stage, based on a standard rating scale score (confirm with trial site). - You d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07537075 · Skyhawk Therapeutics, Inc. Phase 3 · 2 countries By Invitation
By Invitation Phase 3 Est. completion 1 December 2029
🇦🇺 AU🇳🇿 NZ

**Who might be able to join this trial:** - You must have already completed treatment in a previous SKY-0515 treatment study, and the study doctor must feel you followed that study's rules and procedures properly. - You must be able and willing to follow all the requirements of this study, as judged by the study doctor...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01574053 · CHDI Foundation, Inc. Not Applicable · 20 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2062
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇱 CL🇨🇴 CO🇩🇰 DK +12 more

**Who might be able to join this trial:** - People who carry the gene mutation that causes Huntington's disease (HD), either with or without symptoms - People who carry the HD gene mutation and have symptoms that a doctor considers consistent with HD - People who carry the HD gene mutation but do not yet have symptoms...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05509153 · Western Sydney Local Health District Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇦🇺 AU

**Who might be able to join this trial:** - You are able to give your informed consent to take part in the study - You carry an expanded Huntingtin gene with 39 or more CAG repeats (a genetic marker linked to Huntington's disease) - You do not yet have clear physical/movement symptoms of Huntington's disease, based on...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07246941 · Hoffmann-La Roche Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 28 February 2028
🇦🇷 AR🇦🇺 AU🇳🇿 NZ🇬🇧 GB

**Who might be able to join this trial:** **Part 1 (first phase):** - You have been confirmed to have a genetic change linked to Huntington's disease, with a specific gene repeat number greater than 39 - You carry a particular genetic variant (called a SNP) that this treatment is designed to target - Your scores on st...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00608881 · Massachusetts General Hospital Phase 3 · 3 countries Terminated
Terminated Phase 3 Est. completion 1 November 2014
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Huntington's disease (HD) based on symptoms and family history, or confirmed through genetic testing showing a specific gene change linked to HD. - Your HD symptoms are still relatively mild, based on a standard assessment score above 9 (confirm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02494778 · Prilenia Phase 2 · 11 countries Terminated
Terminated Phase 2 Est. completion 12 January 2018
🇦🇺 AU🇦🇹 AT🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇵🇱 PL +3 more

**Who might be able to join this trial:** - You have recently completed the PRIDE HD trial (within the last 6 months, including a 2-week follow-up period), or you previously took part in the Open HART study, or you have finished another future safety and efficacy trial of the drug pridopidine - You may also be able to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03225833 · Wave Life Sciences USA, Inc. Phase 2 · 7 countries Terminated
Terminated Phase 2 Est. completion 11 May 2021
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇵🇱 PL🇬🇧 GB

**Who might be able to join this trial:** - You have been pre-screened and found to have a specific genetic marker linked to the Huntington's disease (HD) gene mutation (confirm with trial site) - You are male or female, aged between 25 and 65 years old, and are able to walk - You have been clinically diagnosed with Hu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03225846 · Wave Life Sciences USA, Inc. Phase 2 · 8 countries Terminated
Terminated Phase 2 Est. completion 10 May 2021
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇵🇱 PL🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been pre-screened and found to have a specific genetic marker (a DNA variation) that is on the same gene as the Huntington's disease (HD) mutation (confirm with trial site) - You are male or female, aged 25 to 65 years old, and are able to walk - You have been clinic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04617847 · Wave Life Sciences USA, Inc. Phase 2 · 7 countries Terminated
Terminated Phase 2 Est. completion 3 May 2021
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇵🇱 PL🇬🇧 GB

**Who might be able to join this trial:** - You must have already completed the earlier Phase 1b/2a study using the drug WVE-120101 (also known as study WVE-HDSNP1-001). **Who may not be able to join:** - You have taken another experimental drug (other than WVE-120101) within the past year, or within a certain time pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04617860 · Wave Life Sciences USA, Inc. Phase 2 · 7 countries Terminated
Terminated Phase 2 Est. completion 29 April 2021
🇦🇺 AU🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇵🇱 PL🇬🇧 GB

**Who might be able to join this trial:** - You previously completed the earlier phase of this study (called WVE-HDSNP2-001) using the drug WVE-120102. **Who may not be able to join:** - You have taken another experimental drug (other than WVE-120102) in the past year, or within a certain period based on how long that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05655520 · Supernus Pharmaceuticals, Inc. Phase 3 · 4 countries Terminated
Terminated Phase 3 Est. completion 20 January 2025
🇦🇺 AU🇨🇦 CA🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You either completed one of two specific earlier related studies (NCT05107128 or NCT05358821), or you meet the requirements to join as a new participant. - You are willing to avoid recreational drugs for the whole study, and avoid alcohol for 48 hours before each visit. - Yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02855476 · University College, London Not Applicable · 10 countries Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇿 NZ🇵🇱 PL🇵🇹 PT🇪🇸 ES +2 more

**Who might be able to join this trial:** - Adults aged 18–75 years (for healthy controls, or people with early or late pre-symptomatic HD, or those with an incomplete form of the HD gene change), adults aged 21–75 years (for people with early, moderate, or advanced HD symptoms), or children aged 11 and older (for juv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03434548 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇬🇧 GB

**Who might be able to join this trial:** - Adults (both male and female) between the ages of 21 and 75 years old. - People with good enough vision and hearing to complete the study's thinking and memory tests, as assessed by the study doctor. - People who are able to understand and sign a consent form agreeing to tak...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04012411 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

Who might be able to join this trial: **For patients:** - You are 18 years old or older - You have national health insurance coverage - You have been diagnosed with Huntington's disease, confirmed by a genetic test showing 35 or more CAG repeats in the HTT gene - You are able and willing to give written consent to tak...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04478734 · Fundación Pública Andaluza para la gestión de la Investigación en Sevi... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇪🇸 ES

**Who might be able to join this trial:** - You must be a legal adult who has been diagnosed with Huntington's disease and is experiencing movement symptoms (such as involuntary movements, muscle stiffness, or slowness) and/or mental or emotional symptoms. - You must have had a genetic test confirming a specific change...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05326451 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed to carry the genetic change that causes Huntington's disease (HD), or you have a family history of HD along with typical symptoms such as involuntary movements (chorea) - Your HD is at an early or moderate stage (stages 1, 2, or 3 on a standard HD rat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05360082 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇧🇪 BE

**Who might be able to join this trial:** *This trial is looking for three different groups of participants:* **Group 1 – Healthy volunteers (10–20 people):** - You are considered to be in good general health based on a doctor's review of your medical history, physical exam, blood tests, and urine tests - You have no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05808153 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 April 2025
🇫🇷 FR

**Who might be able to join this trial:** - You must be between 18 and 65 years old - You must be willing and able to give written consent to participate - You must be covered by a social security or health insurance plan - **If you are a healthy volunteer (control group):** You have no known genetic disease, no famil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05822908 · Vico Therapeutics B. V. Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇱 IL🇳🇱 NL🇬🇧 GB

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the trial. - You are between 25 and 60 years old (inclusive) at the time of signing the consent form. - You have been diagnosed with Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 3 (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06082713 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2031
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 75 years old - You are able to give your informed consent to take part - You are able to read and speak English - You are willing to follow the study procedures, which include fasting overnight, having blood taken, and having a lumbar puncture (a procedure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06203106 · New York Stem Cell Foundation Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 November 2045
🇺🇸 US

Who might be able to join this trial: - You must be at least 30 days old. - You have been diagnosed with a specific condition, disease, or genetic trait of interest — or you are a healthy person serving as a comparison (control). - If you are an adult who can make your own decisions, you must be able to give written co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06414967 · Poitiers University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with Huntington's disease confirmed by a genetic test showing at least 35 CAG repeats in the HTT gene - Your Huntington's disease symptoms are at an early/mild stage, based on a specific rating scale score (UHDRS score o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06444217 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 July 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are between 18 and 70 years old - You are willing and able to sign a consent form agreeing to take part in the study - You have been found to carry a specific genetic change (a CAG repeat number of 36 or more) that is linked to Huntington's disease, whether or not you cur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06448546 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You are willing and able to give your consent to take part in the study - You can read and speak English - You are willing to follow the study's procedures throughout the trial **For the control group (no Huntington's disease), you also need...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06475898 · Huntington Study Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You must be willing and able to give your consent to participate using an electronic device - You must have been told by a doctor that you have Huntington's disease (HD), OR you have had genetic testing that found you carry the gene cha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06546488 · Ohio State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 30 and 65 years old (inclusive) at the time of signing the consent form - You have a genetic confirmation of Huntington's disease, shown by a specific gene marker (CAG repeat of 40 or more) - You have a confirmed clinical diagnosis of Huntington's disease, ver...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06585449 · Alnylam Pharmaceuticals Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 5 July 2028
🇨🇦 CA🇩🇪 DE🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with Stage 2 or early Stage 3 Huntington's disease, as measured by a specific staging system called the HD-ISS Who may not be able to join: - You have a significant brain or nervous system condition other than Huntington's disease - Your immune system is...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06626308 · University Hospital, Grenoble Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - **If you carry the Huntington's disease gene (pre-manifest group):** You have had genetic testing that confirmed you carry the Huntington's disease gene (36 or more CAG repeats in the HTT gene), your movement symptoms are very minimal or not yet present (as measured by a sta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06634628 · CHDI Foundation, Inc. Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 March 2028
🇧🇪 BE

**Who might be able to join this trial:** - You are between 18 and 64 years old (male or female). - Your Body Mass Index (BMI) is between 19 and 35 (a measure of body weight relative to height). - You are able to understand and sign a consent form agreeing to take part. - You are able to follow the study's requirement...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06774443 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇳🇱 NL

Who might be able to join this trial: - You have been diagnosed with Huntington's disease, confirmed by a genetic test showing at least 40 CAG repeats - You are between 18 and 74 years old - You speak Dutch Who may not be able to join: - You have a serious psychiatric condition or another significant neurological cond...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06782230 · IRCCS Policlinico S. Donato Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇮🇹 IT

Who might be able to join this trial: - You have a rare disease yourself, or you are a family member of someone who has a rare disease Who may not be able to join: - There are no stated exclusion criteria for this trial (confirm with trial site) Important: Always verify eligibility with the trial site directly before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06807892 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 October 2027
🇫🇷 FR

**Who might be able to join this trial:** - You must be an adult at the time of joining the trial - You have been diagnosed with Huntington's disease, confirmed by a genetic test - You are in an early stage of Huntington's disease (stage 1 or 2), with specific scores on movement and thinking tests falling within a set...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06826612 · Hoffmann-La Roche Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 12 January 2035
🇺🇸 US

**Who might be able to join this trial:** - Genetic testing (confirmed by the trial's central laboratory) shows a specific mutation in the huntingtin gene — a CAG repeat length of 40 or more. - Brain scans show a certain level of shrinkage in a part of the brain called the striatum (caudate), based on age-related meas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06828471 · Rush University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2027
🇺🇸 US

**Who might be able to join this trial:** *For people with Huntington's Disease:* - You have been diagnosed with Huntington's Disease confirmed by a genetic test - You are between 18 and 65 years old - English is your first language and you can read and write in English - Any medication you take for mood or mental hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06843252 · The University of Texas Health Science Center at San Antonio Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 85 years old and have been confirmed to carry the Huntington's disease (HD) gene mutation and/or have a family history of HD along with typical symptoms such as involuntary movements (chorea). - Your HD is in an early or moderate stage (stages 1, 2, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06853743 · Oslo University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇳🇴 NO

**Who might be able to join this trial:** - You have been confirmed through genetic testing to carry the Huntington's disease (HD) gene, with a result showing 36 or more CAG repeats in the HTT gene. - You have been diagnosed with HD and show clear signs of the disease on a standard neurological examination. - Your HD...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06876857 · University of Central Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 February 2075
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You must be able to give your consent to take part, or if you are unable to do so, a legally authorized person (such as a family member or guardian) can give consent on your behalf. Who may not be able to join: - Anyone under the age of 18...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06941662 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2035
🇺🇸 US

Who might be able to join this trial: - You have tested positive for the gene mutation that causes Huntington's disease (HD) Who may not be able to join: - You have a movement disorder but have tested negative for the Huntington's disease gene mutation Important: Always verify eligibility with the trial site directly...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07010705 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** **If you have Huntington's disease (HD):** - You are between 25 and 65 years old - You have been diagnosed with HD through genetic testing, with a CAG repeat number of 40 or higher, and are at a mild to moderate stage of the disease - You are able to speak and understand Engli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07253038 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇸🇪 SE

**Who might be able to join this trial:** **For people with Huntington's disease (HD):** - You have been diagnosed with Huntington's disease by a doctor - Your genetic test shows a CAG repeat number of 40 or higher (a specific marker found in HD genetic testing) **For people joining as a comparison/control group:** -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07326709 · Novartis Pharmaceuticals Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 2 April 2030
🇦🇷 AR🇨🇦 CA🇨🇳 CN🇮🇱 IL🇰🇷 KR🇨🇭 CH🇹🇼 TW🇬🇧 GB +1 more

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before the study begins - You must be able to walk and move around independently, and be between 21 and 70 years old (inclusive) on the day you sign the consent form - You must have a confirmed genetic diagnosis of Huntingto...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07378644 · Skyhawk Therapeutics, Inc. Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇦🇷 AR🇧🇷 BR🇨🇦 CA🇨🇱 CL🇬🇪 GE

**Who might be able to join this trial:** - You are 25 years old or older. - You have been diagnosed with Huntington's Disease confirmed by a genetic test, showing a specific gene change (CAG repeat of 40 or more in the HTT gene). - Your level of day-to-day functioning, as measured by a standard Huntington's scale call...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07451613 · Leslie Thompson Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - You are able to make your own decisions and are willing to sign a written consent form to take part. - You are between 18 and 65 years old. - You have been diagnosed with Huntington's Disease confirmed through genetic testing. - You are able to have MRI scans, tolerate a brain su...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07513844 · First Affiliated Hospital of Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have been diagnosed with Huntington's disease confirmed by a genetic test, with a specific genetic marker (CAG repeat length of 40 or more) - You have a moderate to severe level of involuntary movements (called chorea), sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07536061 · Sarepta Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2027
🇳🇿 NZ

**Who might be able to join this trial:** - You have been confirmed through genetic testing to have Huntington's disease (HD), with a specific gene repeat length of 40 or more. - Your HD has been assessed and falls into a category called "Stage 2" or "Mild Stage 3" based on a standard HD staging system used by the tria...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Huntington's Disease. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Huntington's Australia is the national body, formed in 2023 from a merger of state associations covering NSW/ACT, QLD, SA/NT, TAS and WA. Victoria is served separately by Huntington's Victoria.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.